OPKO Health, Inc. OPK R2K
Healthcare · Diagnostics & Research · United States
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.
READ MORE ›$1.46
+7.35% 1Y
Market & Price
Market Cap
$1.10B
Current Price
$1.46
High / Low (52W)
$1.58 / $1.10
Beta
1.41
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
93.65
Book Value
$1.67
Price to Book
0.87
P/S
1.90
EV/EBITDA
-10.38
Dividend Yield
-
Profitability & Returns
ROCE
-7.44%
ROE
-16.92%
ROA
-6.36%
Profit Margin
-36.64%
Op Margin
-41.08%
EPS (Latest Qtr)
$-0.07
EPS (TTM)
$-0.27
Balance Sheet & Liquidity
Debt/Equity
0.33
Quick Ratio
2.83
Current Ratio
3.61
Debt
$396.93M
Total Assets
$1.93B
Current Assets
$581.88M
Working Capital
$435.20M
Ownership
Promoter Holding
49.49%
Chg in Prom Hold
-
FII / Inst Holding
27.15%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$1.17B
Total Revenue (TTM)
$581.12M
EBITDA
$-112.49M
Free Cash Flow
$-36.09M
Operating Cash Flow
$-163.30M
Shares Outstanding
755.09M
Gross Margin
14.92%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-15.45%
Profit 5Y
10.43%
Revenue (YoY)
-17.20%
Earnings (YoY)
-
PROS
- Profit CAGR of 10.4% over 5 years.
CONS
- Revenue declined at -15.5% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 81 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OPK OPKO Health, Inc. R2K | 1.46 | - | $1.10B | - | -7.44% | -16.92% | -15.45% | 10.43% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 266.38M | 292.60M | 246.04M | 160.98M | 254.91M | 263.69M | 249.81M | 221.85M | 222.45M | 226.37M | 228.77M | 224.34M | 211.47M | 301.21M | 428.06M | 494.68M | 545.16M | 442.41M | 385.81M | 401.33M | 329.22M | 309.89M | 179.74M | 185.34M | 237.58M | 265.42M | 178.59M | 181.91M | 173.69M | 182.19M | - | - | 149.95M | 156.81M | 151.67M | 148.45M | 124.20M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 107.33M | 107.41M | 101.78M | 84.42M | 78.44M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 42.07M | 51.65M | - | - | 42.62M | 49.40M | 49.89M | 64.03M | 45.76M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 109.79M | 109.38M | 103.41M | 102.34M | 96.77M |
| Operating Income | 28.27M | -23.62M | - | -45.22M | -25.83M | -47.77M | - | -42.61M | -5.11M | -33.46M | - | -75.32M | -47.26M | -39.01M | - | -40.76M | 27.18M | 21.94M | - | 38.44M | 5.57M | 37.83M | - | -72.42M | -10.74M | -87.82M | - | -30.59M | 7.03M | -64.41M | - | -71.47M | -61.67M | - | - | -67.17M | -59.98M | -53.52M | -38.32M | -51.02M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -34.42M | -69.17M | 75.53M | -13.22M | -27.82M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.47M | 70.33M | 11.36M | 11.31M | 10.94M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -73.37M | -162.52M | 41.43M | -46.90M | -60.96M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.77M | -14.08M | 19.80M | -15.66M | -6.11M |
| Net Income | - | - | - | - | - | - | - | -43.11M | -6.20M | -27.66M | -76.07M | -80.76M | -59.81M | -62.01M | -112.35M | -59.13M | 33.70M | 23.72M | 32.30M | 31.08M | -16.19M | 28.74M | -73.78M | -55.43M | -101.65M | -86.09M | -85.23M | -18.27M | -19.64M | -84.47M | -66.48M | -81.84M | -10.30M | - | - | -67.61M | -148.44M | 21.63M | -31.26M | -54.85M |
| Diluted EPS | 0.02 | -0.03 | -0.04 | -0.06 | -0.04 | -0.06 | -0.39 | - | -0.01 | - | - | - | - | - | - | -0.09 | 0.05 | 0.04 | 0.05 | 0.05 | -0.03 | 0.04 | -0.11 | -0.08 | -0.14 | -0.11 | -0.11 | -0.02 | - | -0.11 | - | -0.12 | -0.01 | - | - | -0.10 | -0.19 | 0.03 | -0.04 | -0.07 |
| R&D Expense | 31.35M | 24.42M | - | 26.56M | 33.13M | 32.51M | - | 32.89M | 29.21M | 30.16M | - | 36.53M | 28.29M | 30.02M | - | 21.76M | 17.61M | 18.49M | - | 19.32M | 18.22M | 18.31M | - | 18.31M | 17.25M | 18.79M | - | 32.60M | 18.16M | 19.43M | - | 21.94M | 24.08M | 28.77M | - | 30.84M | 30.34M | 30.08M | - | 29.20M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 1.12B | 966.01M | 990.27M | 901.93M | 1.44B | - | 1.00B | 863.50M | 713.14M | 606.88M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 715.98M | 545.37M | 494.63M | 400.94M |
| Gross Profit | 1.54M | 15.00M | 10.74M | 19.17M | - | - | - | - | - | - | - | - | - | 288.22M | 318.13M | 218.51M | 205.94M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 534.34M | 476.18M | 492.07M | 424.93M |
| Operating Income | -22.15M | -11.14M | -23.19M | -37.27M | -79.63M | -145.81M | -98.48M | -96.55M | -276.44M | -171.20M | -274.05M | 57.71M | - | -246.12M | -158.06M | -273.56M | -218.99M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -270.81M | -65.52M | 135.28M | -41.27M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.06M | 13.51M | 47.47M | 108.46M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -391.52M | -184.32M | -10.36M | -241.36M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | -63.50M | 4.44M | 42.84M | -15.71M |
| Net Income | -30.11M | -18.93M | -1.28M | -29.05M | -114.41M | -171.67M | -30.03M | -48.36M | -305.25M | -153.04M | -314.93M | 30.59M | - | -328.40M | -188.86M | -53.22M | -225.68M |
| Diluted EPS | - | - | - | - | - | - | - | -0.10 | -0.55 | -0.27 | -0.53 | 0.05 | - | -0.46 | -0.25 | -0.08 | -0.30 |
| R&D Expense | 10.84M | 5.95M | 11.35M | 19.52M | 53.90M | 83.57M | 99.49M | 113.87M | 126.44M | 125.59M | 117.87M | 75.32M | 76.85M | 73.89M | 89.59M | 105.21M | 124.03M |
Compounded Sales Growth
| 5 Years: | -15.45% |
| 1 Year: | -17.20% |
Compounded Profit Growth
| 5 Years: | 10.43% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +7.35% |
| 6 Months: | +8.15% |
| 3 Months: | +21.67% |
| 1 Month: | +31.53% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 77.85M | 229.49M | 289.83M | 1.39B | 1.27B | 2.80B | 2.77B | 2.59B | 2.45B | 2.31B | 2.47B | - | 2.17B | 2.01B | 2.20B | 1.93B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 394.52M | 309.48M | 662.09M | 581.88M |
| Cash & Equivalents | 6.68M | 42.66M | 18.02M | 71.52M | 27.36M | 185.80M | 96.91M | 193.60M | 168.73M | 91.50M | 96.47M | 85.45M | 72.21M | - | 153.19M | 95.88M | 431.94M | 369.07M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 74.06M | 65.70M | 56.80M | 65.82M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 127.31M | 123.38M | 118.02M | 90.25M |
| Total Liabilities | - | - | 28.67M | 44.22M | 86.55M | 518.54M | 431.92M | 819.39M | 674.81M | 746.33M | 659.78M | 694.51M | 801.51M | - | 605.61M | 622.48M | 834.76M | 663.99M |
| Current Liabilities | - | - | 27.60M | 18.78M | 52.38M | 91.85M | 83.11M | 251.90M | 263.30M | 312.03M | 288.32M | 249.12M | 375.48M | - | 213.48M | 200.05M | 193.10M | 146.68M |
| Long Term Debt | - | - | - | - | 5.15M | 3.27M | 2.43M | 2.52M | 717.00K | 1.57M | 4.65M | 3.91M | - | - | 219.47M | 222.03M | 422.18M | 333.71M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 305.55M | 326.56M | 504.44M | 396.78M |
| Total Equity | 359.00K | 31.60M | 23.05M | 160.88M | 179.39M | 876.41M | 842.14M | 1.98B | 2.05B | 1.84B | 1.79B | 1.61B | 1.67B | - | 1.56B | 1.39B | 1.37B | 1.27B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 781.31M | 781.94M | 701.35M | 789.92M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -23.46M | -18.71M | -18.50M | -25.41M | -55.65M | -90.38M | 164.02M | 32.05M | -92.08M | -109.14M | -172.52M | 39.48M | - | -95.19M | -28.20M | -183.49M | -178.54M |
| Investing Cash Flow | -22.60M | -2.78M | -14.84M | -24.77M | 30.32M | -5.67M | -99.22M | -20.70M | -46.67M | -26.12M | -13.27M | -18.33M | - | 91.04M | -18.20M | 352.21M | 230.30M |
| Financing Cash Flow | 81.92M | -2.77M | 86.92M | 6.03M | 183.63M | 7.26M | 33.01M | -35.20M | 61.04M | 140.91M | 175.25M | -35.08M | - | 22.97M | -11.30M | 184.17M | -118.06M |
| Capital Expenditure | - | - | - | - | - | - | - | - | - | - | - | - | - | -24.58M | -16.27M | -25.01M | -12.28M |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - | - | - | - | -119.77M | -44.47M | -208.50M | -190.82M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.82M | -57.70M | 352.89M | -66.30M |
| Share Buybacks | - | - | 7.83M | 0 | 0 | - | - | - | - | - | - | - | - | 0 | 0 | 90.22M | 47.04M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.7% | 36.8% | 30.6% | 33.9% |
| Operating Margin % | - | - | - | - | - | - | - | -8.6% | -28.6% | -17.3% | -30.4% | 4.0% | - | -24.5% | -18.3% | -38.4% | -36.1% |
| Net Margin % | - | - | - | - | - | - | - | -4.3% | -31.6% | -15.5% | -34.9% | 2.1% | - | -32.7% | -21.9% | -7.5% | -37.2% |
| ROE % | -95.3% | -82.1% | -0.8% | -16.2% | -13.1% | -20.4% | -1.5% | -2.4% | -16.6% | -8.5% | -19.5% | 1.8% | - | -21.0% | -13.6% | -3.9% | -17.8% |
| ROCE % | - | -22.2% | -11.0% | -15.7% | -6.1% | -12.3% | -3.9% | -3.9% | -12.1% | -7.9% | -13.3% | 2.8% | - | -12.6% | -8.7% | -13.6% | -12.3% |
Shareholding Pattern
Insiders
49.49%
Institutions
27.15%
Public Float
53.74%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Rubric Capital Management LP | 6.33% | 47.79M | $69.78M |
| 2 | Blackrock Inc. | 4.80% | 36.23M | $52.90M |
| 3 | Vanguard Portfolio Management LLC | 1.96% | 14.77M | $21.56M |
| 4 | Vanguard Capital Management LLC | 1.92% | 14.50M | $21.17M |
| 5 | Geode Capital Management, LLC | 1.50% | 11.30M | $16.50M |
| 6 | State Street Corporation | 1.26% | 9.50M | $13.87M |
| 7 | Goldman Sachs Group Inc | 1.02% | 7.68M | $11.21M |
| 8 | UBS Group AG | 0.80% | 6.07M | $8.86M |
| 9 | Whitefort Capital Management, LP | 0.56% | 4.25M | $6.21M |
| 10 | Northern Trust Corporation | 0.48% | 3.62M | $5.28M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OPK
No recent headlines available.